Why Pathologists Get Sued: Melanoma False-Negatives, the Specimen Mix-Up, and the 87% Diagnostic-Error Problem

By John Mahoney · June 2026 · 9 min read

Pathology is the specialty most attorneys never name as a defendant — which is precisely why it is worth understanding. Pathologists rarely meet the patient, generate few claims, and sit several steps removed from the harm. But when they are wrong, the error is usually a missed cancer that was caught, biopsied, and then mislabeled as benign, allowing a curable disease to progress for months or years. The result is a specialty with one of the lowest claim frequencies in medicine and one of the highest per-claim payouts — and an allegation profile that is almost entirely about one thing: the diagnostic read.

This guide walks through what the closed-claims data shows about why pathologists get sued — how rare but how severe the claims are, which specimens drive them, and how interpretive error and the specimen mix-up create two very different kinds of cases — for plaintiff and defense med-mal attorneys triaging a pathology file.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Closed-claims figures vary by source, era, and definition, and the standard of care is jurisdiction- and fact-specific. Always verify the controlling standard and obtain independent expert re-review of the actual slides before relying on any generalization.

The Frequency and Severity Reality

Pathology is a low-frequency specialty. The Jena et al. analysis (NEJM 2011) classed it among the lower-risk fields, with roughly 5% of pathologists facing a claim in a given year and a smaller fraction facing a paid claim. Paid-claim rates have been declining: one large analysis (JAMA, covering 1992–2014) reported roughly 6.9 paid claims per 1,000 physician-years early in the period, falling by about half by 2009–2014.

By severity, it punches far above its frequency. Reported mean indemnity ran around $411,000 across 1992–2014 and rose to roughly $474,000 in the later 2009–2014 window — figures that in some analyses exceed even high-payout surgical specialties, despite pathology's far lower claim count. The reason is mechanism: the missed-cancer claim is a death-and-progression claim, and roughly a quarter of paid pathology claims reportedly involved patient death. Yet despite the high average, pathology has the lowest reported share of catastrophic (over $1M) payouts of any specialty (around 4.2%). It is a high-floor, moderate-ceiling specialty: the typical viable claim is serious, but the runaway verdict is the exception.

The Dominant Allegation: Diagnostic Error, Almost Exclusively

No specialty is more concentrated in a single allegation type. Diagnosis-related claims — failure to diagnose, misdiagnosis, or false-negative interpretation — reportedly account for about 87% of paid pathology claims (JAMA, 1992–2014), the highest diagnostic-error share of any specialty. The remaining slivers:

• Specimen-specific interpretive error, broken out by tissue type — breast specimens are reportedly the single largest category (around 15.5% combining biopsy, FNA, and frozen section), with melanoma/skin and gynecologic cytology false-negatives close behind.
• System and operational errors — pre- and post-analytic failures: specimen mix-ups, mislabeling, lost specimens, transcription and report errors, and failure to communicate critical values. These are a rising share of claims.
• Intraoperative consultation error — frozen-section misinterpretation and deferral discordance.

The allegation prior for pathology is the diagnostic read. But the experienced screener immediately asks a second question that splits the specialty in two: is this an interpretive error (the pathologist looked at the right tissue and called it wrong) or a system error (the wrong tissue, a mislabeled slide, a result that never reached the clinician)? Those are different cases with different proof problems, and should never be lumped together.

The "Cannot-Miss" Specimens and Conditions

Pathology claims cluster around a short list of cancers where a false-negative is catastrophic and the interpretive difficulty is real:

• Malignant melanoma. Historically the single most common driver, with reportedly around 70% of melanoma claims being false-negatives — a melanoma called a benign Spitz or dysplastic nevus or a dermatofibroma. The line between a benign and malignant melanocytic lesion is among the hardest in surgical pathology, which is exactly why it generates claims.
• Breast cancer. False-negatives on biopsy, FNA, and frozen section — the largest combined specimen category.
• Cervical / gynecologic cytology (Pap smear). False-negative interpretation missing dysplasia or carcinoma.
• Prostate cancer. Gleason-grading errors and specimen mix-ups on needle biopsies.
• System errors. Specimen mix-ups, mislabeling, and failure to report a critical finding to the treating clinician — the non-interpretive claims that can be the strongest of all, because they do not require a battle of expert eyes over a slide.

These map onto the cancer category of the cross-specialty "Big Three." A false-negative read on a melanoma, breast, cervical, or prostate specimen — with documented disease progression in the interval — is the high-merit signal in this specialty.

The Contributing Factors That Decide Who Pays

The contributing factors split along the same interpretive/system line that defines the specialty:

• Diagnostic / interpretive (cognitive) error is the dominant driver. In frozen-section discordance studies, roughly 46% of discrepancies were interpretation errors and roughly 54% were process or sampling errors — a reminder that even at the microscope, not every miss is a "wrong read."
• Technical, sampling, and pre-analytic factors — gross sampling (reported around 33%) and histologic sampling (around 17%) errors in frozen-section discrepancy data. Tissue never put on the slide cannot be diagnosed.
• System and communication breakdowns — specimen mix-ups, mislabeling, transcription errors, and failure to communicate critical values. These post-analytic failures are a growing share of claims and often the most provable, since they do not turn on a subjective interpretation.
• Documentation gaps — an absent differential diagnosis in the report, missing clinical context, or unclear provisional labeling. As in every specialty, report quality is a defensibility lever independent of whether the read was correct.

The communication-and-documentation theme that recurs across all specialties appears here in a specialty-specific form: the critical value never phoned to the clinician, and the report that buried a hedge or omitted the differential. A report that documents diagnostic uncertainty and recommends additional studies is far more defensible than a confident, unhedged miss.

Strong Case vs. Weak Case in Pathology

The interpretive/system split largely determines case strength — useful to both sides.

What strengthens a plaintiff's case

• A system error — a specimen mix-up, a mislabeled slide, a critical value never communicated — which avoids the "two experts disagree about a slide" problem and presents as a discrete, provable deviation.
• A false-negative on a high-consequence specimen (melanoma, breast, cervical, prostate) where independent re-review shows the malignancy was present and identifiable on the original slide.
• A documented progression interval — the cancer advanced in stage between the misread and the correct diagnosis — establishing causation, with a report that showed no documented uncertainty.

What strengthens the defense

• A genuinely difficult interpretive call — a borderline melanocytic lesion where reasonable, qualified pathologists disagree. The standard of care is reasonable interpretation, not perfect hindsight.
• A report that documented diagnostic uncertainty and recommended further studies or re-excision — shifting responsibility downstream.
• A sampling limitation outside the pathologist's control — the diagnostic tissue was not in the specimen submitted.
• A causation gap — the delay did not change stage, treatment, or prognosis.

As in the other diagnosis-driven specialties, pathology cases frequently turn on causation: a false-negative read only pays if the delay it caused actually worsened the outcome. The strongest cases pair a clear, independently confirmed misread with a documented stage progression; the weakest are interpretive disputes over borderline lesions with no causal harm.

The Expert and Merit Questions Come First

Pathology cases live or die on expert re-review of the actual slides, so the expert is the case — and the qualification fight starts at the pre-suit gate. The pathologist who signs the certificate of merit must typically be qualified to opine against the defendant pathologist, often with subspecialty alignment (dermatopathology for a melanoma case), and the same match-and-reliability questions feed directly into a later motion to exclude. Confirm the expert match before you retain, because in a specialty where the entire dispute is one expert's read against another's, an excludable expert is a lost case.

Bottom Line

Pathology is the textbook low-frequency, high-severity specialty: few claims, but a high average payout driven by missed cancers that progressed while a curable disease was labeled benign. Diagnostic error dominates the allegations — reportedly about 87% of paid claims, the highest of any field — with melanoma false-negatives, breast/cervical/prostate specimens, and specimen mix-ups the recurring drivers. The decisive split is interpretive versus system error: the mix-up and the uncommunicated critical value are the cleaner, more provable claims, while the borderline-lesion read is where the standard-of-care battle is hardest.

For both sides, the work is the same: separate the system error from the interpretive dispute, obtain independent slide re-review, establish the stage-progression window for causation, and confirm the expert's subspecialty match and merit filing early. Verify the read against the actual slides, not the report alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →